Akash Mukherjee

Researcher

UAMS

Also affiliated: MedStar Washington Hospital Center (2014); Houston Methodist (2015–2018); The University of Texas MD Anderson Cancer Center (2018–2024); Indian Institute of Technology Bombay (2018); Kempegowda Institute of Medical Sciences (2021); Cornell University (2017–2018); University of Arkansas Medical Center (2024); Mahatma Gandhi Memorial Medical College (2002); Maharaja Yeshwantrao Hospital (2002); Rabindranath Tagore International Institute of Cardiac Sciences (2012); Methodist Hospital (2016–2024); Winthrop Rockefeller Foundation (2023); Oncology Hematology Care (2024–2025); Weill Cornell Medicine (2017–2018); Indian Institute of Technology BHU (2016); Indian Institute of Technology Delhi (2023–2025); MedStar Health (2015); Banaras Hindu University (2016)

Faculty Researcher

10 h-index 68 pubs 301 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Akash Mukherjee's research focuses on outcomes and treatment strategies for B-cell acute lymphoblastic leukemia (ALL) in adults, particularly concerning brexucabtagene autoleucel therapy. He has investigated the impact of prior treatments on patient responses and analyzed real-world outcomes from collaborative efforts like the ROCCA study. Mukherjee also studies the role of the gut microbiota, specifically *Bacteroides ovatus*, in mitigating graft-versus-host disease following hematopoietic stem cell transplantation. His work contributes to understanding complex immune-related syndromes, such as immune effector cell-associated HLH-like syndrome. Mukherjee has a h-index of 10 with 68 total publications and 289 citations. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Muthu Veeraputhiran, Ankur Varma, César Sánchez, and Mamatha Gaddam.

Metrics

h-index: 10
Publications: 68
Citations: 301

Selected Publications

The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2025)

Bone Marrow Transplantation 1 citation DOI OpenAlex
Gut Microbiome Diversity and Composition Changes Post Allogeneic Hematopoietic Stem Cell Transplant (AlloSCT): A Single-Center Prospective Analysis (2024)

Blood DOI OpenAlex
The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2024)

Transplantation and Cellular Therapy DOI OpenAlex
Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care (2024)

Transplantation and Cellular Therapy 5 citations DOI OpenAlex
Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy (2024)

Transplantation and Cellular Therapy 4 citations DOI OpenAlex
Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)

Blood 5 citations DOI OpenAlex
Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (2023)

Blood 14 citations DOI OpenAlex
The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2023)

Blood 1 citation DOI OpenAlex
Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study (2023)

Blood 1 citation DOI OpenAlex
Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) (2023)

Blood 5 citations DOI OpenAlex
The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2023)

Blood 4 citations DOI OpenAlex
Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms (2023)

Blood DOI OpenAlex
Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity (2023)

Cancers 31 citations DOI OpenAlex
Epidemiology of Aggressive NK-Cell Leukemia in the United States: A SEER Population-Based Study (2021)

Blood 4 citations DOI OpenAlex
Clinical Outcome of Refractory Lymphoma Patients with Non Response to Chimeric Antigen Receptor T Cell Therapy (2021)

Blood DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

77 Collaborators 44 Institutions 1 Country

Top Collaborators

Ibrahim Aldoss City Of Hope National Medical Center (US) 10 shared publications

Gregory W. Roloff University of Chicago (US) 10 shared publications

Noam E. Kopmar Fred Hutch Cancer Center (US) 10 shared publications

Marc S. Schwartz University of Colorado Anschutz Medical Campus (US) 10 shared publications

Simone E. Dekker Fred Hutch Cancer Center (US) 9 shared publications

Nikeshan Jeyakumar Stanford University (US) 9 shared publications

Timothy E. O’Connor Loyola University Medical Center (US) 9 shared publications

Kaitlyn C. Dykes University of California, San Diego (US) 9 shared publications

Mohamed Ahmed Cedars-Sinai Medical Center (US) 9 shared publications

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) 2023 · 14 citations
Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care 2024 · 5 citations
The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) 2023 · 4 citations
Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) 2023 · 4 citations
Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) 2023 · 4 citations